Bank of Montreal Can Sells 134,103 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Bank of Montreal Can decreased its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 90.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,532 shares of the company's stock after selling 134,103 shares during the quarter. Bank of Montreal Can's holdings in Acelyrin were worth $46,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. RPO LLC purchased a new position in Acelyrin during the 4th quarter valued at about $46,000. Virtu Financial LLC purchased a new stake in shares of Acelyrin in the third quarter worth approximately $50,000. Intech Investment Management LLC grew its position in Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock valued at $83,000 after purchasing an additional 11,040 shares in the last quarter. Wells Fargo & Company MN grew its position in Acelyrin by 21.9% during the fourth quarter. Wells Fargo & Company MN now owns 52,014 shares of the company's stock valued at $163,000 after purchasing an additional 9,332 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Acelyrin by 146.0% in the 4th quarter. American Century Companies Inc. now owns 78,868 shares of the company's stock valued at $248,000 after buying an additional 46,802 shares during the period. 87.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Acelyrin

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now directly owns 671,753 shares in the company, valued at $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 13.60% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SLRN. Citigroup decreased their target price on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. HC Wainwright dropped their target price on Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $9.60.

Acelyrin Trading Up 0.5 %

Acelyrin stock traded up $0.01 during mid-day trading on Monday, hitting $2.18. 275,327 shares of the company's stock were exchanged, compared to its average volume of 1,207,597. Acelyrin, Inc. has a 1-year low of $1.85 and a 1-year high of $7.25. The stock has a 50 day moving average of $2.47 and a two-hundred day moving average of $3.34. The stock has a market cap of $219.98 million, a P/E ratio of -0.89 and a beta of 1.12.

Acelyrin (NASDAQ:SLRN - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.07. As a group, research analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.